Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study

doi:10.3748/wjg.v23.i41.7459

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 41

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8626)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

545

WORD

256

HTML

4405

Figures (1-4)

153

Tables (1-4)

126

Sum=5485

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1119

Download

2022

Sum=3141

Nov 7, 2017 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

World J Gastroenterol. Nov 7, 2017; 23(41): 7459-7469
Published online Nov 7, 2017. doi: 10.3748/wjg.v23.i41.7459

Table 2 Biochemical parameters: Baseline visit vs final visit

	Baseline visit			Visit at 48 wk
	TDF	LAM+ADV	P value	TDF	LAM+ADV	P value
	average (range)	average (range)	P value	average (range)	average (range)	P value
AST (UI/mL)	26.66 (9.00-74.00)	26.69 (15.00-69.00)	0.904	26.41 (14.00-71.00)	26.05 (18.00-52.00)	0.916
ALT (UI/mL)	25.41 (12.00-62.00)	23.62 (13.60-40.00)	0.646	26.32 (12.00-55.00)	27.29 (17.00-51.00)	0.965
Phosphorus (mmol/dL)	3.00 (1.80-4.00)	2.84 (1.90-3.80)	0.263	3.08 (1.70-4.40)	2.95 (2.00-3.70)	0.832
Urea (mg/dL)	36.14 (20.00-53.00)	36.96 (18.00-61.90)	0.698	38.29 (25.00-57.00)	38.69 (22.00-53.00)	0.479
Serum creatinine (mg/dL)	0.88 (0.70-1.16)	0.89 (0.60-1.35)	0.912	0.88 (0.69-1.16)	0.92 (0.60-1.27)	0.396
Glomerular filtration rate (mL/min/1.73 m²)	94.13 (66.95-121.03)	97.48 (60.47-157.83)	0.922	93.11 (66.75-123.55)	93.14 (59.14-151.26)	0.468
Creatinine clearance (mL/min)	103.52 (65.57-185.25)	105.43 (64.79-166.22)	0.831	100.85 (60.84-149.66)	102.32 (60.26-157.5)	0.308

ADV: Adefovir dipivoxil; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; LAM: Lamivudine; TDF: Tenofovir dipivoxil fumarate.

Citation: Rodríguez M, Pascasio JM, Fraga E, Fuentes J, Prieto M, Sánchez-Antolín G, Calleja JL, Molina E, García-Buey ML, Blanco MÁ, Salmerón J, Bonet ML, Pons JA, González JM, Casado MÁ, Jorquera F, the TENOSIMP-B Research Group. Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study. World J Gastroenterol 2017; 23(41): 7459-7469
URL: https://www.wjgnet.com/1007-9327/full/v23/i41/7459.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i41.7459